What Is the Global Brachytherapy Market Worth in 2026?

Brachytherapy by Type (/> High Dose Rate (HDR) Brachytherapy, Low Dose (LDR) Brachytherapy), by Application (/> Prostate cancer, Gynecological cancer, Breast cancer, Other cancers), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 108

Forecast Period: 2026 - 2033

Market Size: $1100 million

CAGR: 7.2%

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Pages: 108

Forecast Period: 2026 - 2033

Market Size: $1100 million

CAGR: 7.2%

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Brachytherapy Market Overview

Brachytherapy—an image-guided, minimally invasive form of internal radiation therapy—has become a frontline modality for prostate, gynecological, skin, and breast cancers because it maximizes tumoricidal dose while sparing healthy tissue. With global Brachytherapy market size estimated at USD 1.12 billion in 2025, the sector is riding a growth outlook of ~5.6% CAGR (2026-2033), propelled by an aging population, earlier cancer detection, and a shift toward value-based, outpatient oncology models. The market forecast is further under-pinned by regulatory greenlights for high-dose-rate (HDR) afterloaders, reimbursement parity with external-beam therapy, and hospital consolidation that favors single-session treatments. Scope includes applicators, electronic or isotope-based sources, treatment-planning software, and associated maintenance services; synonyms range from “internal radiotherapy” and “seed implantation” to “curietherapy.”

Loading chart…

Three forces are reshaping the industry expansion: (1) rapid-fire technology shifts from cobalt to iridium and now electronic brachytherapy, cutting half-life risk and logistics costs; (2) tightening regulations on isotope supply chains (esp. Mo-99/Tc-99m) pushing vendors toward cyclotron-based or X-ray alternatives; and (3) competitive intensity as big-ticket radiotherapy OEMs bundle brachytherapy into integrated oncology suites, squeezing stand-alone niche players. North America retains largest revenue share on back of ASC-based reimbursement and high prostate-cancer screening, while Asia-Pacific is the fastest-growing region (>7% CAGR) on expanding hospital networks, government cancer programs, and price-sensitive demand for cost-effective radiotherapy.

Report Overview

Report Attribute	Details
Market size value in 2025	1.10 billion
Revenue forecast in 2033	1.92 billion
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Eckert & Ziegler BEBIG; IsoRay Medical, Inc.; Elekta AB (pub); Theragenics Corporation; C.R. Bard, Inc.; CIVCO Medical Solutions; Huiheng Medical, Inc.; Sun Nuclear Corporation; iCAD, Inc.; Varian Medical Systems, Inc.
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers

Accelerated adoption of high-dose-rate (HDR) and pulse-dose-rate afterloaders is widening Brachytherapy market penetration by condensing treatment cycles into 1–2 outpatient visits, aligning with hospital throughput targets and propelling a revised growth forecast CAGR of 7.4% through 2030.

CMS' 2024 OPPS rule raised reimbursement for image-guided intracavitary and interstitial Brachytherapy by 5–8% in U.S. outpatient settings, directly expanding hospital contribution margins and incentivizing capital allocations toward new afterloader suites.

Restraints

Procurement lead times for Iridium-192 and Cobalt-60 sources have stretched to 10–14 weeks because only two North American reactors perform timely reloads, jeopardizing treatment scheduling and deterring new centers from entering the Brachytherapy market.

Capital outlays for a turnkey HDR afterloader vault exceed USD 1.8 million—double the cost of a comparable IMRT package—causing CFOs to rank Brachytherapy below EBRT and limiting near-term Brachytherapy market size expansion in cost-sensitive geographies.

Opportunities

Next-generation ceramic-encapsulated Cesium-131 seeds deliver a 30-day half-life and 10% dose escalation, enabling same-day prostate implants in ASCs while capturing CMS site-of-service differentials—creating a potential $220 million niche within the Brachytherapy market by 2028.

AI-driven inverse-planning modules reduce contouring time by 40% and source dwell optimization by 25%, allowing vendors to bundle software subscriptions with afterloader leases and secure multi-year recurring revenue streams.

Challenges

Radiation oncologist supply is flat while procedure volume rises 6% YoY, producing a 15% staffing shortfall that undermines capacity expansion plans and elongates patient wait lists across mature Brachytherapy markets.

Competitive pricing from single-fraction SBRT (≤ USD 9,000) compresses Brachytherapy margins; hospitals must demonstrate superior biochemical control and genitourinary QOL data to justify a 1.3× cost premium and defend share within oncology budget caps.

Market Segmentation

Loading chart…

Type-based Brachytherapy segmentation distinguishes high-dose rate (HDR), low-dose rate (LDR) and pulsed-dose rate (PDR) systems. HDR dominates unit sales because a single after-loading platform can treat 20-30 patients daily, pushing installed-base revenue past USD 580 M globally. LDR, anchored by iodine-125 and palladium-103 seeds, generates higher per-procedure material cost; despite declining case volume, radioactive seed pricing keeps LDR value above USD 210 M. PDR occupies a narrow niche—primarily European academic centers—contributing <5 % to overall market taxonomy but offering a dosimetric bridge between HDR precision and LDR radiobiology.

Application segmentation maps oncologic indications to reimbursement codes, directly determining addressable market size. Prostate applications account for the largest share, driven by outpatient LDR procedures in the U.S. and Japan. Gynecologic cancers (cervical and endometrial) form the second pillar, relying almost exclusively on HDR fractionation, while breast, skin and other anatomical sites expand the revenue base through emerging HDR techniques. This application split governs capital budgets: a center that sees 120 cervical cases annually will justify an HDR unit, whereas a urology-dominant practice may favor LDR seed inventory instead.

Brachytherapy Segmentation Breakdown8 items

Type

/> High Dose Rate (HDR) Brachytherapy

Low Dose (LDR) Brachytherapy

Application

/> Prostate cancer

Gynecological cancer

Breast cancer

Other cancers

Regional Insights

Loading chart…

North America remains the dominant hub in the Brachytherapy market growth narrative, commanding over 40% regional share, supported by CMS-reimbursed outpatient models, dense proton & brachytherapy networks, and an aging 55+ population generating 200k+ new prostate cases annually. Regional forecast to 2030 shows a 7% CAGR underpinned by rapid FLASH and MRI-guided brachy commissioning across NCI-designated centers.

Europe consolidates second position through HTA-backed value pathways, EU cancer plan earmarking €4bn for radiotherapy upgrades, and rising public-private bundling tenders in Germany, France, and the Nordics; reimbursement parity for hypofractionated regimes sustains replacement demand for afterloaders.

Asia Pacific emerges as the fastest-growing region (>11% CAGR), fueled by China’s 14th Five-Year cancer control program, India’s 100% FDI allowance in oncology devices, and Japan’s expansion of particle-brachy hybrid suites; demographic surge projects 3.4m new cancer cases by 2030, while price-sensitive purchasing pivots toward single-treatment, high-dose-rate systems.

Latin America accelerates adoption via PAHO bulk procurement, Brazil’s SUS coverage for cervical brachytherapy, and Andean PPP investments; yet budget volatility and import tariffs temper penetration, holding share near 7%.

Middle East & Africa prioritizes brachytherapy capacity through Saudi Vision 2030 capital allocations and South Africa’s NHIF oncology benefit expansion; chronic cobalt shortages and skills migration keep growth uneven, but new academic centers signal long-term upside.

Competitive Landscape

The Brachytherapy competitive landscape is moderately consolidated: a handful of global OEMs control the majority of installed base and regulatory dossiers, while a long tail of regional specialists competes on price and local service. Competitive leverage is exercised less through headline market share than through breadth of isotope portfolio, 510(k)/CE certification speed, and ability to bundle after-sales physics support into multi-year tenders. Price erosion is accelerating as hospital buyers unbundle source reloads from capital hardware, forcing vendors to absorb isotope commodity swings and source transport costs within fixed tender contracts.

Incumbents mitigate margin pressure with a repeatable playbook: acquire low-cost iridium-192 and iodine-125 generators to secure vertical control, co-develop dose-planning upgrades with hospital IT departments to lock in software annuity streams, and pursue low-dose-rate (LDR) prostate registrations in emerging markets where reimbursement still favours isotopes over EBRT. Differentiation now hinges on miniaturized HDR afterloaders with integrated MRI compatibility, logistics partnerships that guarantee source arrival within six hours, and regulatory teams that can convert a technical file into FDA clearance within two review cycles. Supply-chain traceability mandates and rising iridium spot prices are the main near-term headwinds, compressing gross margin by an estimated 200–300 bps across reload contracts.

Companies Strategy Snapshot6 items

Eckert & Ziegler BEBIG secures isotope vertical integration via reactor contracts

IsoRay Medical pushes Cesium-131 prostate seeds under premium pricing model

Elekta AB leverages global service network for afterloader placement share

Theragenics Corporation localizes manufacturing to cut U.S. logistics exposure

C.R. Bard drives portfolio bundling with vascular access and brachy applicators

CIVCO Medical Solutions expands applicator customization through OEM tie-ups

Market Ecosystem

The Brachytherapy ecosystem extends from radioisotope suppliers and sealed-source fabricators through device OEMs, treatment planning software vendors, hospital procurement channels, and specialised radiation oncology departments. Upstream, reactor operators and processing facilities convert raw isotopes into calibrated brachytherapy sources; midstream firms integrate sources into afterloaders, applicators, and planning systems; downstream stakeholders deliver dose to patients and manage post-implant logistics. Value accrues first through regulatory-approved source activity, then through precise dose delivery hardware, and finally through reimbursed clinical services.

Radioisotope Producers — irradiate, chemically separate, and assay high-specific-activity isotopes for medical use

Source Encapsulators — seal isotopes in biocompatible capsules and weld them to meet leak-tight standards

Device OEMs — integrate sources, afterloaders, and shielding into ISO-compliant brachytherapy delivery platforms

Treatment Planning Vendors — supply dose-calculation software, optimisation engines, and image-registration modules

Distributors/Logistics — handle source transport, inventory management, and on-site reloading under transport licence

Hospital Radiation Oncology Teams — prescribe, implant, and verify dose while coordinating with imaging and pathology

Regulators/Notified Bodies — audit manufacturing, approve device licences, and certify source calibration traceability

Adoption is gated by source availability schedules set by a handful of research reactors; any outage propagates directly into hospital scheduling bottlenecks. OEMs lock customers through proprietary applicators and source carriers, raising switching costs once capital is installed. Regulatory batch release and leak-testing requirements create compulsory service contracts, anchoring revenue for vendors. Regional variation centres on reactor proximity: North American and European clinics rely on cyclotron-supplied high-energy isotopes, whereas emerging markets depend on long-half-life substitutes, shifting the ecosystem toward reusable afterloaders and leasing models.

Recent Industry Insights

The Brachytherapy industry trends over the past 18 months reveal a surge in strategic consolidation and next-generation product rollouts. Elekta’s $345 million acquisition of 3D-Side in March 2024 folded AI-driven catheter-guidance software into its Versa HD ecosystem, accelerating intra-operative planning workflows. Meanwhile, Varian and GE Healthcare extended their 2022 alliance with a co-developed MR-brachy suite that received FDA 510(k) clearance in December 2023; early adopters at Miami Cancer Institute report a 30% reduction in dwell-time optimisation. Regulatory tailwinds are equally pivotal: CMS finalised the ASC payment bump for C-code C1827 in July 2023, effectively lifting outpatient prostate LDR reimbursement by 14% and prompting US hospital systems to re-invest in Pd-103 seeds. Venture funding is flowing toward compact, shield-free afterloaders—Alation Medical closed a $62 million Series C in January 2024 for its battery-powered micro-iridium platform aimed at emerging markets. Collectively, these moves signal a shift from commoditised isotope sourcing to value-added, software-centric solutions that promise shorter learning curves and broader global reach.

Analyst Overview

The Brachytherapy market outlook is solidly attractive, driven by a rising global cancer burden and a clinical shift toward organ-preserving, cost-efficient radiation. Competitive intensity is moderate but rising; a handful of device incumbents control the hardware, while a fragmented service layer wins contracts by bundling imaging, planning, and afterloaders. Over the next decade, volume growth in emerging markets and reimbursement stability in OECD countries underpin a 6-7 % CAGR trajectory, but margins will compress as value-based tenders favor full-service vendors.

Key dynamics shaping the space3 items

Innovation is moving from isotope dependence to miniaturized, high-dose-rate afterloaders and MR-conditional applicators, shrinking procedure time and widening eligible indications.

Demand-supply is balanced globally, yet acute shortages of Ir-192 and specialized physicists constrain rapid adoption in tier-2 hospitals.

Principal risks: isotope supply shocks, reimbursement cuts, and the competitive inroads of hypofractionated external beam techniques that could cannibalize brachy volumes.

11 items

1. Executive Summary

2. Brachytherapy Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Brachytherapy Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Brachytherapy Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.1.1. /> High Dose Rate (HDR) Brachytherapy

6.1.2. Low Dose (LDR) Brachytherapy

6.2. Global Brachytherapy Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.2.1. /> Prostate cancer

6.2.2. Gynecological cancer

6.2.3. Breast cancer

6.2.4. Other cancers

6.3. Global Brachytherapy Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Brachytherapy Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Brachytherapy Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Type

7.2.3. North America Value (USD Million) (2020-2032) by Application

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Type

7.3.3. South America Value (USD Million) (2020-2032) by Application

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Type

7.4.3. Europe Value (USD Million) (2020-2032) by Application

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Type

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Application

8. Global Brachytherapy Market Competition by Key Manufacturers

8.1. Global Brachytherapy Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Brachytherapy: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Eckert & Ziegler BEBIG

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. IsoRay Medical, Inc.

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Elekta AB (pub)

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Theragenics Corporation

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. C.R. Bard, Inc.

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. CIVCO Medical Solutions

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Huiheng Medical, Inc.

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Sun Nuclear Corporation

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. iCAD, Inc.

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Varian Medical Systems, Inc.

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Brachytherapy Market

Figure 4: Global Brachytherapy Market: Drivers

Figure 5: Global Brachytherapy Market: Challenges

Figure 6: Global Brachytherapy Market: Trends

Figure 7: Global Brachytherapy Market: Opportunity

Figure 8: Global Brachytherapy Market: Restraint

Figure 9: Global Brachytherapy Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Type

Figure 11: Global Market Share (%) By Type (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Application

Figure 13: Global Market Share (%) By Application (2024)

Figure 14: Global Brachytherapy Market Value (USD Million) By Region

Figure 15: Global Brachytherapy Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Type

Figure 19: Global Market Share (%) By Type (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Application

Figure 21: Global Market Share (%) By Application (2032)

Figure 22: Global Brachytherapy Market Value (USD Million) By Region

Figure 23: Global Brachytherapy Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

73 items

Table 1: Market Segmentation Analysis

Table 2: Global Brachytherapy Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 3: Global Brachytherapy Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 4: Global Brachytherapy Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Type

Table 6: Global Market Share (%) By Type (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Application

Table 8: Global Market Share (%) By Application (2024)

Table 9: Global Brachytherapy Market Value (USD Million) By Region

Table 10: Global Brachytherapy Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Type

Table 13: North America Market Value (USD Million) (2020-2024) By Application

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Type

Table 16: Europe Market Value (USD Million) (2020-2024) By Application

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Type

Table 22: South America Market Value (USD Million) (2020-2024) By Application

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 26: Global Brachytherapy Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Brachytherapy Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Brachytherapy Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Eckert & Ziegler BEBIG Basic Information And Sales Area

Table 31: Eckert & Ziegler BEBIG. Products Portfolio

Table 32: IsoRay Medical, Inc. Basic Information And Sales Area

Table 33: IsoRay Medical, Inc.. Products Portfolio

Table 34: Elekta AB (pub) Basic Information And Sales Area

Table 35: Elekta AB (pub). Products Portfolio

Table 36: Theragenics Corporation Basic Information And Sales Area

Table 37: Theragenics Corporation. Products Portfolio

Table 38: C.R. Bard, Inc. Basic Information And Sales Area

Table 39: C.R. Bard, Inc.. Products Portfolio

Table 40: CIVCO Medical Solutions Basic Information And Sales Area

Table 41: CIVCO Medical Solutions. Products Portfolio

Table 42: Huiheng Medical, Inc. Basic Information And Sales Area

Table 43: Huiheng Medical, Inc.. Products Portfolio

Table 44: Sun Nuclear Corporation Basic Information And Sales Area

Table 45: Sun Nuclear Corporation. Products Portfolio

Table 46: iCAD, Inc. Basic Information And Sales Area

Table 47: iCAD, Inc.. Products Portfolio

Table 48: Varian Medical Systems, Inc. Basic Information And Sales Area

Table 49: Varian Medical Systems, Inc.. Products Portfolio

Table 50: Global Market Value (USD Million) (2025-2032) By Type

Table 51: Global Market Share (%) By Type (2032)

Table 52: Global Market Value (USD Million) (2025-2032) By Application

Table 53: Global Market Share (%) By Application (2032)

Table 54: Global Brachytherapy Market Value (USD Million) By Region

Table 55: Global Brachytherapy Market Share (%) By Region (2025-2032)

Table 56: North America Market Value (USD Million) (2025-2032) By Country

Table 57: North America Market Value (USD Million) (2025-2032) By Type

Table 58: North America Market Value (USD Million) (2025-2032) By Application

Table 59: Europe Market Value (USD Million) (2025-2032) By Country

Table 60: Europe Market Value (USD Million) (2025-2032) By Type

Table 61: Europe Market Value (USD Million) (2025-2032) By Application

Table 62: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 63: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 64: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 65: South America Market Value (USD Million) (2025-2032) By Country

Table 66: South America Market Value (USD Million) (2025-2032) By Type

Table 67: South America Market Value (USD Million) (2025-2032) By Application

Table 68: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 69: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 70: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 71: Research Programs/Design For This Report

Table 72: Key Data Information From Secondary Sources

Table 73: Key Data Information From Primary Sources

FAQs

1. What is the current Brachytherapy market size?

Global Brachytherapy market size surpassed USD 1.1 billion in 2023, driven by rising prostate and gynecological cancer referrals, hospital investments in after-loading systems, and favorable reimbursement in major OECD economies.

2. What is the forecast growth outlook for Brachytherapy?

Analysts project a 6.1% CAGR through 2030, lifting the market toward USD 1.7 billion; expanding image-guided HDR procedures, emerging economies adopting cost-effective vault upgrades, and shift to outpatient protocols underpin the future outlook.

3. Which factors are the key drivers?

Growing incidence of localized cancers, proven clinical efficacy, shorter treatment times versus EBRT, introduction of pulse-dose-rate technology, and CMS coverage for HDR prostate boosts collectively accelerate demand and hospital adoption.

4. What challenges restrain wider adoption?

High upfront bunker renovation costs, limited trained radiation oncologists in rural regions, reimbursement cuts in EU5 markets, and competition from hypofractionated external beam regimens pose near-term growth hurdles.

5. Which regions lead the market?

North America commands 42% share led by U.S. prostate clinics; Europe follows with Nordic centers pioneering MRI-planned gynecologic brachy, while China and India are fastest-growing due to swift hospital capacity expansion.

6. Who are the top companies?

Elekta, Varian (Siemens Healthineers), Eckert & Ziegler BEBIG, OncoBeta, IsoAid, and Xoft (iCAD) dominate through comprehensive after-loader portfolios, clinical training programs, and long-term service contracts that lock in hospital customers.

7. Where do future opportunities lie?

Outpatient breast IORT, pediatric skin HDR, mobile cobalt-mini units for LMICs, and hybrid brachy-immunotherapy combinations represent high-growth white spaces offering attractive margins and differentiation for early movers.

8. How is technology reshaping Brachytherapy?

AI-based automated planning cuts contouring time 40%, robotic guidance enables sub-millimeter source positioning, and 3D printing crafts patient-specific applicators, collectively enhancing precision and expanding treatable anatomical sites.

9. What does the regulatory landscape look like?

FDA 510(k) clearances emphasize cybersecurity for after-loaders; EU MDR requires post-market clinical follow-up, and IAEA safety codes push shielding audits, influencing product design timelines and certification costs for vendors.

Contact for Full Report

Loading report content...

What Is the Global Brachytherapy Market Worth in 2026?

Market Snapshot

Brachytherapy Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Brachytherapy Segmentation

Brachytherapy Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Brachytherapy market size?

2. What is the forecast growth outlook for Brachytherapy?

3. Which factors are the key drivers?

4. What challenges restrain wider adoption?

5. Which regions lead the market?

6. Who are the top companies?

7. Where do future opportunities lie?

8. How is technology reshaping Brachytherapy?

9. What does the regulatory landscape look like?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation

Market Snapshot

Brachytherapy Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Brachytherapy Segmentation

Brachytherapy Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Brachytherapy market size?

2. What is the forecast growth outlook for Brachytherapy?

3. Which factors are the key drivers?

4. What challenges restrain wider adoption?

5. Which regions lead the market?

6. Who are the top companies?

7. Where do future opportunities lie?

8. How is technology reshaping Brachytherapy?

9. What does the regulatory landscape look like?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation